A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer

Key facts

Sponsor

Indiana University School of Medicine

Principal Investigator

Patrick J Loehrer, MD

Indiana University School of Medicine

Intervention

bevacizumab(drug)

Enrollment

18 enrolled

Eligibility

18 years · All sexes

Timeline

2006 – 2007

Study locations (1)

• Indiana University Cancer Center, Indianapolis, Indiana, United States

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Thymoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06730308
  Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma
  Sun Yat-sen University
• RECRUITINGNANCT06029621
  Robot-assisted vs VATS for Thymoma
  Shanghai Pulmonary Hospital, Shanghai, China
• ACTIVE NOT RECRUITINGNANCT05682742
  Clinical Investigation of the da Vinci Surgical System
  Intuitive Surgical
• RECRUITINGNANCT02633553
  Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
  Fudan University
• ACTIVE NOT RECRUITINGPHASE2NCT03076554
  A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
  National Cancer Institute (NCI)
• ACTIVE NOT RECRUITINGNANCT03968315
  An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
  M.D. Anderson Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT01025089
  Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
  Memorial Sloan Kettering Cancer Center

See all trials for Thymoma →